We provide you with 20 years of free, institutional-grade data for LTRN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LTRN. Explore the full financial landscape of LTRN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about LTRN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Lantern Pharma Inc(NASDAQ:LTRN) 
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant...
Website: http://www.lanternpharma.com
Founded: 2013
Full Time Employees: 4
CEO: Panna L. Sharma
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends